Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Lucia Farina, Francesco Spina, Anna Guidetti, Paolo Longoni, Fernando Ravagnani, Anna Dodero, Vittorio Montefusco, Carmelo Carlo-Stella & Paolo Corradini. (2014) Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. Leukemia & Lymphoma 55:2, pages 331-336.
Read now
Read now
Articles from other publishers (17)
Maria Tavakoli Ardakani, Hamid Reza Ahadi, Hossein Bonakchi, Sayeh Parkhideh, Farzaneh Tavakoli, Mohammad Reza Moshari, Masoud Soleimani & Abbas Hajifathali. (2022) Evaluation of CD34+ Cell Count at Different Time Points Following Plerixafor Administration in Autologous Hematopoietic Stem Cell Transplantation. International Journal of Cancer Management 15:6.
Crossref
Crossref
Kenneth W. Douglas, Maria Gilleece, Patrick Hayden, Hannah Hunter, Peter R. E. Johnson, Charlotte Kallmeyer, Ram K. Malladi, Shankara Paneesha, Rachel Pawson, Michael Quinn, Kavita Raj, Deborah Richardson, Stephen Robinson, Nigel Russell, John Snowden, Anna Sureda, Eleni Tholouli, Kirsty Thomson, Mike Watts & Keith M. Wilson. (2017) UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high‐dose chemoradiotherapy for patients with malignancy. Journal of Clinical Apheresis 33:1, pages 46-59.
Crossref
Crossref
Marc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, Julia Krzykalla, Natalia Becker, Katja Weisel, Richard Noppeney, Hans Martin, Hans W. Lindemann, Mathias Haenel, Axel Nogai, Christof Scheid, Hans Salwender, Roland Fenk, Ullrich Graeven, Peter Reimer, Martin Schmidt-Hieber, Martin Goerner, Ingo G. H. Schmidt-Wolf, Stefan Klein, Anthony D. Ho, Hartmut Goldschmidt & Patrick Wuchter. (2017) Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. European Journal of Haematology 99:1, pages 42-50.
Crossref
Crossref
. 2017. Hematopoietic Cell Transplants. Hematopoietic Cell Transplants
79
103
.
Antony P. Martin, Sarah Richards, Alan Haycox, Rachel Houten, Claire McLeod, Barbara Braithwaite, Jack O. Clark, Joanne Bell & Richard E. Clark. (2016) Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial. Journal of Clinical Apheresis 31:5, pages 434-442.
Crossref
Crossref
Sebastian Giebel, Maria Sadus-Wojciechowska, Kazimierz Halaburda, Joanna Drozd-Sokolowska, Agnieszka Wierzbowska, Jacek Najda, Wlodzimierz Mendrek, Malgorzata Sobczyk-Kruszelnicka, Mateusz Nowicki, Jerzy Holowiecki & Tomasz Czerw. (2015) Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group. Annals of Hematology 95:2, pages 263-269.
Crossref
Crossref
IGNACIO GARCÍA-ESCOBAR, LUCÍA PARRILLA, LAURA MONTEJANO ORTEGA, DANIEL CASTELLANOS, MARÍA ÁNGELES MONTALBÁN PALLARÉS & HERNÁN CORTÉS-FUNÉS. (2014) Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors. Molecular and Clinical Oncology 2:6, pages 923-926.
Crossref
Crossref
B M Haverkos, A McBride, L O'Donnell, D Scholl, B Whittaker, S Vasu, S Penza, L A Andritsos, S M Devine & S M Jaglowski. (2014) An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor. Bone Marrow Transplantation 49:8, pages 1052-1055.
Crossref
Crossref
M Mohty, K Hübel, N Kröger, M Aljurf, J Apperley, G W Basak, A Bazarbachi, K Douglas, I Gabriel, L Garderet, C Geraldes, O Jaksic, M W Kattan, Z Koristek, F Lanza, R M Lemoli, L Mendeleeva, G Mikala, N Mikhailova, A Nagler, H C Schouten, D Selleslag, S Suciu, A Sureda, N Worel, P Wuchter, C Chabannon & R F Duarte. (2014) Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 49:7, pages 865-872.
Crossref
Crossref
Roberto Sorasio, Margherita Bonferroni, Mariella Grasso, Giuliana Strola, Davide Rapezzi, Dario Marenchino, Cristina Di Marco, Claudia Castellino, Daniele Mattei, Nicola Mordini, Francesca Fiore, Ivana Celeghini, Anna Borra, Annalisa Ghiglia & Andrea Gallamini. (2014) Peripheral Blood CD34+ Percentage at Hematological Recovery after Chemotherapy Is a Good Early Predictor of Harvest: A Single-Center Experience. Biology of Blood and Marrow Transplantation 20:5, pages 717-723.
Crossref
Crossref
L Farina, A Guidetti, F Spina, L Roncari, P Longoni, F Ravagnani, C Carlo-Stella & P Corradini. (2013) Plerixafor ‘on demand’: results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. Bone Marrow Transplantation 49:3, pages 453-455.
Crossref
Crossref
Sergio Giralt, Luciano Costa, Jeffrey Schriber, John DiPersio, Richard Maziarz, John McCarty, Paul Shaughnessy, Edward Snyder, William Bensinger, Edward Copelan, Chitra Hosing, Robert Negrin, Finn Bo Petersen, Damiano Rondelli, Robert Soiffer, Helen Leather, Amy Pazzalia & Steven Devine. (2014) Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. Biology of Blood and Marrow Transplantation 20:3, pages 295-308.
Crossref
Crossref
Amnon Peled, Michal Abraham, Irit Avivi, Jacob M. Rowe, Katia Beider, Hanna Wald, Lena Tiomkin, Lena Ribakovsky, Yossi Riback, Yaron Ramati, Sigal Aviel, Eithan Galun, Howard Laurence Shaw, Orly Eizenberg, Izhar Hardan, Avichai Shimoni & Arnon Nagler. (2014) The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma. Clinical Cancer Research 20:2, pages 469-479.
Crossref
Crossref
Shan Yuan, Auayporn Nademanee, Amrita Krishnan, Neil Kogut, Sepideh Shayani & Shirong Wang. (2013) Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent. Transfusion 53:12, pages 3244-3250.
Crossref
Crossref
Grzegorz Władysław Basak, Kazimierz Hałaburda & Wiesław Wiktor Jędrzejczak. (2012) Bieżące poglądy dotyczące miejsca pleryksaforu w mobilizacji autologicznych krwiotwórczych komórek macierzystych. Acta Haematologica Polonica 43:4, pages 317-325.
Crossref
Crossref
M E Horwitz, J P Chute, C Gasparetto, G D Long, C McDonald, A Morris, D A Rizzieri, K M Sullivan & N J Chao. (2011) Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplantation 47:8, pages 1051-1055.
Crossref
Crossref
E. Jantunen, V. Varmavuo, A. Juutilainen, T. Kuittinen, E. Mahlamäki, P. Mäntymaa & T. Nousiainen. (2012) Kinetics of blood CD34+ cells after chemotherapy plus G-CSF in poor mobilizers: Implications for pre-emptive plerixafor use. Annals of Hematology 91:7, pages 1073-1079.
Crossref
Crossref